Dengue (IgG) by ELISA at Test Zone Diagnostic Center

Dengue (IgG) by ELISA at Test Zone Diagnostic Center

Dengue fever, caused by the dengue virus (DENV)—a single-stranded RNA virus belonging to the Flaviviridae family—presents a major public health challenge in tropical and subtropical regions, including Pakistan. Transmitted primarily by the bite of infected Aedes aegypti and Aedes albopictus mosquitoes, the virus exists as four distinct serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). Accurate diagnosis is critical for clinical management, epidemiological tracking, and patient risk stratification. The Dengue (IgG) by ELISA test at Test Zone Diagnostic Center is a specialized serological assay designed to detect immunoglobulin G (IgG) antibodies directed against the envelope proteins of the dengue virus.

Unlike acute-phase biomarkers such as the Dengue NS1 antigen or Dengue IgM antibodies, which indicate active or very recent infection, IgG antibodies appear later in the course of the disease. In a primary infection, IgG levels rise slowly, typically becoming detectable around 8 to 10 days after the onset of symptoms, and persist for life, providing lifelong immunity to that specific serotype. However, in secondary infections—which occur when an individual is infected with a different serotype—IgG levels rise rapidly and robustly within 1 to 2 days of symptom onset. This rapid anamnestic response is a key marker of secondary infection, which carries a significantly higher risk of severe clinical manifestations, such as Dengue Hemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS), due to antibody-dependent enhancement (ADE).

The Enzyme-Linked Immunosorbent Assay (ELISA) technology utilized for this test provides high sensitivity and specificity. By immobilizing dengue viral antigens on a solid-phase microtiter plate, the assay captures specific IgG antibodies present in the patient’s serum. A subsequent enzymatic reaction produces a colorimetric change proportional to the concentration of IgG antibodies, which is measured photometrically. This quantitative or semi-quantitative approach offers superior diagnostic value compared to rapid immunochromatographic card tests, ensuring that clinicians receive highly reliable data to guide patient care.

Clinical Procedure: What to Expect

Patient Preparation

• No fasting is required for the Dengue (IgG) by ELISA test. Patients can consume their regular diet and fluids prior to the blood draw.
• Inform the healthcare provider or laboratory technician about any ongoing medications, particularly immunosuppressants, anticoagulants, or anti-platelet therapies, as these can influence bleeding times or immune responses.
• Wear a short-sleeved shirt or clothing with sleeves that can be easily rolled up to facilitate access to the venipuncture site.
• Ensure adequate hydration by drinking plenty of water before the test, which helps make the veins more accessible and simplifies the collection process.
• If you have a history of fainting, dizziness, or anxiety during blood draws, inform the phlebotomist beforehand so they can take appropriate measures, such as performing the draw while you are lying down.

During the Procedure

The patient is comfortably seated or placed in a recumbent position. The phlebotomist identifies a suitable vein, typically the median cubital vein in the antecubital fossa of the arm. The area is thoroughly cleansed with an antiseptic solution (such as 70% isopropyl alcohol) and allowed to air dry to prevent specimen contamination and local infection. A sterile tourniquet is applied a few inches above the selected site to increase venous pressure and make the vein more prominent.

Using a sterile, single-use needle attached to an evacuated tube system (vacutainer), the phlebotomist gently inserts the needle into the vein. A blood sample (approximately 3 to 5 mL) is collected into a red-top or gold-top (serum separator) tube. The tourniquet is released, the needle is carefully withdrawn, and immediate pressure is applied to the puncture site with a sterile cotton ball or gauze pad to promote hemostasis. An adhesive bandage is applied over the site. The entire collection process takes less than five minutes and involves minimal discomfort, comparable to a brief pinprick. The collected blood sample is labeled with the patient’s unique identifiers and sent to the laboratory for processing, where the serum is separated via centrifugation before performing the ELISA assay.

When is a Dengue (IgG) by ELISA Performed?

Evaluation of Past Dengue Virus Exposure

Physicians request the Dengue (IgG) by ELISA test to determine whether a patient has had a prior infection with the dengue virus. Because many dengue infections are asymptomatic or present as mild, self-limiting febrile illnesses, patients may not be aware of their previous exposure. Identifying past exposure is highly relevant for individuals living in or traveling to endemic areas, as it establishes their baseline immunological status regarding flaviviruses.

Identification of Secondary Dengue Infection Risk

A primary clinical utility of this test is assessing the risk of severe dengue complications. If a patient presenting with acute febrile symptoms has a rapidly rising or highly elevated level of Dengue IgG early in the course of the illness, it strongly indicates a secondary infection. Since secondary heterologous infections are the primary risk factor for antibody-dependent enhancement (ADE)—leading to vascular leakage, thrombocytopenia, and severe bleeding—this test helps clinicians identify high-risk patients who require close monitoring and aggressive supportive care.

Investigation of Prolonged or Resolving Febrile Illness

In cases where a patient presents late in the course of a febrile illness (typically more than 7 to 10 days after onset), molecular tests like RT-PCR and early serological markers like NS1 antigen may yield negative results due to the clearance of viremia. In such scenarios, the Dengue (IgG) by ELISA test, especially when performed alongside a Dengue IgM test, is crucial for confirming a recent infection and establishing a retrospective diagnosis of dengue fever.

Epidemiological Surveillance and Public Health Assessment

Public health authorities and epidemiologists utilize the Dengue (IgG) by ELISA test to conduct seroprevalence studies within specific populations. By measuring the prevalence of IgG antibodies in a community, researchers can estimate the proportion of the population that has been exposed to the virus, map transmission patterns, evaluate the effectiveness of vector control programs, and prepare healthcare systems for potential seasonal outbreaks.

Differential Diagnosis of Acute Tropical Fevers

Patients presenting with acute febrile illnesses in endemic regions often present a diagnostic challenge due to overlapping clinical features of various diseases, such as malaria, typhoid fever, leptospirosis, chikungunya, and Zika virus. The Dengue (IgG) by ELISA test helps differentiate dengue from these other infectious etiologies, allowing for appropriate, targeted clinical management and preventing the misuse of antibiotics.

What Does a Dengue (IgG) by ELISA Detect?

The Dengue (IgG) by ELISA test detects and measures specific IgG antibodies directed against the dengue virus. The clinical findings and interpretations include:

• Absence of Dengue IgG Antibodies: Indicates no detectable past exposure to the dengue virus, suggesting susceptibility to primary infection.
• Presence of Dengue IgG Antibodies: Confirms previous exposure to one or more serotypes of the dengue virus.
• Primary Infection Profile: Characterized by negative or low-level IgG antibodies early in the disease, with seroconversion occurring late in the convalescent phase.
• Secondary Infection Profile: Indicated by a rapid, high-titer rise in IgG antibodies during the acute phase of the illness.
• Past Resolved Infection: Stable, low-to-moderate levels of IgG antibodies in the absence of acute symptoms or IgM antibodies.
• Cross-Reactivity with Other Flaviviruses: Potential detection of antibodies elicited by other flaviviruses, such as Zika, West Nile, or Yellow Fever viruses, or vaccination (e.g., Japanese Encephalitis).
• Maternal Antibody Transfer: Detection of IgG antibodies in newborns due to passive placental transfer from a dengue-immune mother.
• Seroconversion: A four-fold or greater rise in IgG antibody titers between acute and convalescent-phase serum samples, confirming recent infection.
• Equivocal Results: Borderline antibody levels that require retesting with a new sample collected 10 to 14 days later.
• Immune Status Assessment: Determination of baseline immunity prior to participation in clinical trials or vaccination programs.
• Co-infection Identification: Helping identify concurrent infections when evaluated alongside other serological panels.
• Vascular Leakage Risk Stratification: High IgG titers in acute phase correlating with increased risk of plasma leakage.
• Severe Thrombocytopenia Risk Correlation: Association of high IgG titers with rapid platelet destruction in secondary infections.
• Dengue Hemorrhagic Fever (DHF) Susceptibility: Identification of patients with pre-existing IgG who are susceptible to DHF upon reinfection.
• Dengue Shock Syndrome (DSS) Risk Assessment: Clinical warning indicator for potential circulatory collapse in secondary cases.
• Viremia Clearance Phase: Confirmation of immune response during the phase where viral replication is declining.
• Chronic Phase Monitoring: Long-term tracking of antibody persistence in longitudinal clinical studies.
• Post-Vaccination Immune Response: Evaluation of humoral immunity following administration of dengue vaccines.
• False Negative due to Immunosuppression: Delayed or absent IgG response in immunocompromised individuals despite infection.
• False Positive due to Autoimmune Factors: Potential interference from rheumatoid factor or other autoantibodies.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center, we prioritize clinical accuracy and efficiency. The Dengue (IgG) by ELISA test is processed using advanced automated ELISA platforms to ensure precise results. Typically, the turnaround time for this test is within 24 to 48 hours from the time of sample collection. Patients and referring physicians are notified via SMS once the report is finalized. Reports can be securely accessed and downloaded online through the official Test Zone Diagnostic Center patient portal, or collected in person from our main facility or collection centers.

Dengue (IgG) by ELISA Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Dengue IgG Antibody Level	Negative (No detectable antibodies)	Positive (Presence of IgG antibodies)
Primary Infection Kinetics	No early IgG rise; slow seroconversion	Late, low-to-moderate IgG titer rise
Secondary Infection Kinetics	No rapid IgG spike	Rapid, high-titer IgG spike in acute phase
Immune Status	Susceptible to primary DENV infection	Immune to previously exposed serotype(s)
Cross-Reactivity Check	No cross-reacting antibodies	False positive due to Zika or West Nile antibodies
Maternal Antibody Transfer	Negative in infants of non-immune mothers	Positive in newborns of dengue-immune mothers
Seroconversion Status	Stable antibody levels	Four-fold or greater rise in paired sera

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for Dengue (IgG) by ELISA?

• Experienced healthcare professionals and pathologists supervising all serological assays.
• Patient-focused care designed to ensure a comfortable and stress-free testing experience.
• Quality diagnostic services utilizing state-of-the-art automated ELISA systems.
• Professional reporting with clear, easy-to-understand clinical interpretations.
• Modern diagnostic approach adhering to international quality control standards.
• Comfortable environment at all collection points and main diagnostic facilities.
• Convenient location, ensuring easy accessibility for patients across the region.
• Commitment to accurate diagnosis, providing clinicians with reliable data for patient management.